



Monday 13th January 2020

Contact: Lak Sahota
Email: lak.sahota@alturix.com
Telephone: +44 (0)1908 038090

New Pharmaceutical Company ALTURiX Launches

Announced today, ALTURiX – a new British company - has conditionally acquired the rights to a portfolio of well-known medicines which are prescribed widely by the NHS. The mission set out by the founders of the new company is to reliably provide branded products at an appropriate price. ALTURiX has been created and shaped to provide these high quality medicines to the NHS with streamlined efficiency.

The company portfolio includes three heritage, branded products acquired from Novartis - all proven and acknowledged to improve patients' health. ALTURiX will continue to reliably supply these products to the NHS and other international markets, using its high-quality manufacturing partner based in Switzerland. This is in keeping with the company's commitment to reliably deliver high-quality products, at a sensible price.

At the same time, the company is growing through a programme of new product introductions. NACSYS® (600mg effervescent tablets), an effervescent formulation of the mucolytic n-acetylcysteine, was launched recently. This launch demonstrates the company's commitment to reliably supply products, affordably, in markets where there are currently limited options available to patients and the NHS. NACSYS® is predicted to save the NHS up to £8m annually compared with currently priced alternatives.¹

The ALTURiX Board has over fifty years of experience within the healthcare sector. Broad experience drawn from clinical practice, surgery, pharmacy, sales, marketing, finance and general management, means that the Board brings together the skills and expertise needed to deliver on its vision, resulting in a reputation for delivering cost efficiency to its UK and international customers.

“Our values of integrity, partnership and reliability are incredibly important to us. We continually focus on these three pillars, so that - through partnerships with our customers - we will continue to build our reputation as we rapidly expand our portfolio of launched products.” Stated Dr Simon Clough, one of the ALTURiX Founders.

- Ends-

Reference 1. Data On File. Budget Impact Model: based on average CCG of approximately 314,000 patients. Accessed January 2020.

Further information overleaf

About ALTURiX

Headquartered in Milton Keynes, ALTURiX can trace its origins back to 1998 when the rights for its three heritage products – Phosphate Sandoz™, Sando-K®, and Slow Sodium® – were acquired from Novartis. These products have since been reliably supplied to the NHS, helping to improve patients' health.

The company's stated aim is to provide high-quality medicines at appropriate prices in markets where current prescriber and patient choices are limited, and to thereby develop a reputation for reliability, and delivery of value. Recent launches include the effervescent mucolytic, NACSYS®.

Company Contacts: Lak Sahota BPharm MRPharmS
Founder and Director
Email: lak.sahota@alturix.com

Simon Fisher
Founder and Director
Email: simon.fisher@alturix.com

Company Address: 287 Upper Fourth Street
Milton Keynes
MK9 1EH
United Kingdom

Telephone: +44 (0)1908 038090

Website: www.alturix.com

Email: info@alturix.com

About NACSYS®

NACSYS® is an effervescent tablet containing 600mg of acetylcysteine and is indicated for the treatment of adults to reduce the viscosity of airway secretions to facilitate expectoration, especially during periods of bronchitis. NACSYS® was launched in November 2017 as an alternative to carbocisteine in the treatment of respiratory disorders in adults such as bronchitis, emphysema, mucoviscidoses and bronchiectasis.

For complete product information, please see the Summary of Product Characteristics that can be found on www.medicines.org.uk

About Phosphate Sandoz™

Phosphate Sandoz™ is an effervescent tablet containing anhydrous sodium acid phosphate, and is indicated for hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis and malignancy, hypophosphataemia associated with vitamin D resistant rickets and vitamin D resistant hypophosphataemic osteomalacia.

For complete product information, please see the Summary of Product Characteristics that can be found on www.medicines.org.uk

About Sando-K®

Sando-K® is an effervescent tablet containing both potassium chloride and potassium bicarbonate, and is indicated for the prevention and treatment of hypokalaemia.

Hypokalaemia can be caused by potassium depleting drugs such as frusemide, thiazide diuretics, corticosteroids, carbenoxolone and cardiac glycosides. It can also be commonly caused by severe diarrhoea, vomiting or fistulas; Acid-base disturbances such as alkalosis, renal tubular acidosis and states in which there is aldosterone excess such as Cushing syndrome; Decreased intake of potassium due to malnutrition, alcoholism, and elderly patients with deficient diets. Since Sando-K® contains chloride, it can also be used to treat hypochloraemic alkalosis.

For complete product information, please see the Summary of Product Characteristics that can be found on www.medicines.org.uk

About Slow Sodium®

Slow Sodium® is a coated, modified release tablet containing high doses of sodium chloride and is indicated for the treatment and prophylaxis of clinically evident sodium chloride deficiency.

For complete product information, please see the Summary of Product Characteristics that can be found on www.medicines.org.uk

- Ends-